Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PTPRB | P23467 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9016334 | 0.87 | LMNA (0.53) | LMNASMN1; SMN2KDM4EALDH1A1GAA | |
| SCHEMBL6361849 | 0.86 | LMNA (0.51) | LMNASMN1; SMN2KDM4EALDH1A1TSHR | |
| SCHEMBL333132 | 0.82 | LMNA (0.45) | LMNASMN1; SMN2KDM4EALDH1A1GAA | |
| SCHEMBL332859 | 0.82 | LMNA (0.54) | LMNASMN1; SMN2KDM4EALDH1A1GAA | |
| Ethyl Cartrizoate SCHEMBL2110540 | 0.82 | LMNA (0.47) | LMNASMN1; SMN2KDM4EALDH1A1GAA | |
| SCHEMBL8230945 | 0.81 | LMNA (0.53) | LMNASMN1; SMN2KDM4EALDH1A1TSHR | |
| SCHEMBL1665843 | 0.81 | LMNA (0.46) | LMNASMN1; SMN2KDM4EALDH1A1TSHR | |
| SCHEMBL9016363 | 0.81 | LMNA (0.46) | LMNASMN1; SMN2KDM4EALDH1A1TSHR | |
| SCHEMBL9413528 | 0.80 | LMNA (0.45) | LMNASMN1; SMN2KDM4EALDH1A1TSHR | |
| SCHEMBL9413518 | 0.80 | LMNA (0.45) | LMNASMN1; SMN2KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275094-A2 | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions | Elan Pharma International Limited (IE) | 2011-01-19 | — | — | EP | claimed |
| EP-0601616-A1 | Iodinated aroyloxy carboxamides and contrast agents containing them | NanoSystems L.L.C. (US) | 1994-06-15 | — | — | EP | claimed |
| JP-6228067-A | — | — | None | — | — | JP | disclosed |
| US-20210251900-A1 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY | BAXTER HEALTHCARE SA (CH) | 2021-08-19 | — | — | US | disclosed |
| US-11052043-B2 | Sustained-release injectable formulation | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2021-07-06 | — | — | US | disclosed |
| US-10952965-B2 | Compositions and methods for drug delivery | BAXTER INTERNATIONAL INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10722463-B2 | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier | ZULI HOLDINGS LTD. (IL) | 2020-07-28 | — | — | US | disclosed |
| US-20180193265-A1 | COMPOSITIONS AND METHODS USING SAME FOR DELIVERING AGENTS INTO A TARGET ORGAN PROTECTED BY A BLOOD BARRIER | ZULI HOLDINGS LTD. (IL) | 2018-07-12 | — | — | US | disclosed |
| US-9943481-B2 | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier | BIOREST LTD. (IL) | 2018-04-17 | — | — | US | disclosed |
| EP-2317982-B1 | METHODS OF PROCESSING COMPOSITIONS CONTAINING MICROPARTICLES | BAXTER INT (US) | 2017-10-11 | — | — | EP | disclosed |
| US-9364443-B2 | Compositions and methods for drug delivery | BAXTER INTERNATIONAL, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-0804162-A1 | BUTYLENE OXIDE-ETHYLENE OXIDE BLOCK COPOLYMER SURFACTANTS AS STABILIZER COATINGS FOR NANOCRYSTAL FORMULATION | NanoSystems L.L.C. (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5587143-A | ADSORBED ON SURFACE | NANOSYSTEMS L.L.C. (US) | 1996-12-24 | — | — | US | disclosed |
| US-5569448-A | FOR PARTICLES CONTAINING THERAPEUTIC OR DIAGNOSTIC AGENTS; AUTOCLAVE STABILITY | NANO SYSTEMS L.L.C. (US) | 1996-10-29 | — | — | US | disclosed |
| US-5565188-A | Polyalkylene block copolymers as surface modifiers for nanoparticles | NANOSYSTEMS L.L.C. (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996022766-A1 | SULFATED NONIONIC BLOCK COPOLYMER SURFACTANTS AS STABILIZER COATINGS FOR NANOPARTICLE COMPOSITIONS | NANOSYSTEMS L.L.C. (US) | 1996-08-01 | — | — | WO | disclosed |
| WO-1996000567-A1 | BUTYLENE OXIDE-ETHYLENE OXIDE BLOCK COPOLYMER SURFACTANTS AS STABILIZER COATINGS FOR NANOCRYSTAL FORMULATION | NANOSYSTEMS L.L.C. (US) | 1996-01-11 | — | — | WO | disclosed |
| JP-H06228067-A | IODINATED AROYLOXY CARBOXAMIDE COMPOUND AND X-RAY IMAGING COMPOSITION CONTAINING THE SAME | STERLING WINTHROP INC | 1994-08-16 | — | — | JP | disclosed |
| EP-0601616-A1 | Iodinated aroyloxy carboxamides and contrast agents containing them | NanoSystems L.L.C. (US) | 1994-06-15 | — | — | EP | disclosed |
| US-5260478-A | Contrast agents in x-ray imaging compositions; medical diagnosis | STERLING WINTHROP INC. (US) | 1993-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251900-A1 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY | SGMS1, CETP, APOB | LMNA 615/4885SMN1; SMN2 1151/4885KDM4E 3773/4885 |
| US-10952965-B2 | Compositions and methods for drug delivery | SGMS1, CETP, APOB | LMNA 615/4885SMN1; SMN2 1151/4885KDM4E 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.